Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1959 1
1970 1
1971 3
1972 1
1973 1
1975 2
1976 1
1977 1
1978 2
1979 5
1980 2
1981 10
1982 3
1983 6
1984 1
1985 6
1986 1
1987 4
1988 4
1989 6
1990 3
1991 3
1992 5
1993 4
1994 2
1995 3
1996 4
1997 2
1998 3
1999 2
2000 6
2001 3
2002 7
2003 12
2004 6
2005 14
2006 7
2007 11
2008 17
2009 8
2010 9
2011 12
2012 14
2013 7
2014 6
2015 10
2016 5
2017 9
2018 6
2020 7
2021 3
2022 6
2023 8
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

268 results

Results by year

Filters applied: . Clear all
Page 1
A decade of experience with genetically tailored pig models for diabetes and metabolic research.
Zettler S, Renner S, Kemter E, Hinrichs A, Klymiuk N, Backman M, Riedel EO, Mueller C, Streckel E, Braun-Reichhart C, Martins AS, Kurome M, Keßler B, Zakhartchenko V, Flenkenthaler F, Arnold GJ, Fröhlich T, Blum H, Blutke A, Wanke R, Wolf E. Zettler S, et al. Among authors: riedel eo. Anim Reprod. 2020 Aug 26;17(3):e20200064. doi: 10.1590/1984-3143-AR2020-0064. Anim Reprod. 2020. PMID: 33029223 Free PMC article. Review.
Systematic review of hearing loss in dental professionals.
Hartland JC, Tejada G, Riedel EJ, Chen AH, Mascarenhas O, Kroon J. Hartland JC, et al. Among authors: riedel ej. Occup Med (Lond). 2023 Oct 20;73(7):391-397. doi: 10.1093/occmed/kqad084. Occup Med (Lond). 2023. PMID: 37682842 Free PMC article.
Phase 1b study of enzalutamide plus CC-115, a dual mTORC1/2 and DNA-PK inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC).
Zhao JL, Antonarakis ES, Cheng HH, George DJ, Aggarwal R, Riedel E, Sumiyoshi T, Schonhoft JD, Anderson A, Mao N, Haywood S, Decker B, Curley T, Abida W, Feng FY, Knudsen K, Carver B, Lacouture ME, Wyatt AW, Rathkopf D. Zhao JL, et al. Among authors: riedel e. Br J Cancer. 2024 Jan;130(1):53-62. doi: 10.1038/s41416-023-02487-5. Epub 2023 Nov 18. Br J Cancer. 2024. PMID: 37980367 Clinical Trial.
PROMISE Registry: A prostate cancer registry of outcomes and germline mutations for improved survival and treatment effectiveness.
Paller CJ, Barata PC, Lorentz J, Appleman LJ, Armstrong AJ, DeMarco TA, Dreicer R, Elrod JAB, Fleming M, George C, Heath EI, Hussain MHA, Mao S, McKay RR, Morgans AK, Orton M, Pili R, Riedel E, Saraiya B, Sigmond J, Sokolova A, Stadler WM, Tran C, Macario N, Vinson J, Green R, Cheng HH; PROMISE Trial Investigators. Paller CJ, et al. Among authors: riedel e. Prostate. 2024 Feb;84(3):292-302. doi: 10.1002/pros.24650. Epub 2023 Nov 14. Prostate. 2024. PMID: 37964482
268 results